Gelesis Holdings Current Ratio 2021-2022 | GLS

Gelesis Holdings current ratio from 2021 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Gelesis Holdings Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.06B $0.08B 0.69
2022-06-30 $0.06B $0.07B 0.89
2022-03-31 $0.07B $0.05B 1.42
2021-12-31 $0.07B $0.10B 0.65
2021-09-30 $0.00B $0.00B 0.13
2021-06-30 $0.00B $0.00B 0.39
2021-03-31 $0.00B $0.00B 0.45
2020-12-31 $0.00B 0.00
2020-09-30 $0.00B $0.00B 19.25
2020-06-30 $0.00B $0.00B 0.15
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00